Telman Deborah H, an insider at Gilead Sciences Inc (GILD), acquired 79,641 shares of the company on November 11, 2025, at a price of $60.75 per share, totaling $4.84 million. Following this transaction, Deborah holds 79,641 shares of Gilead.
This purchase underscores a potential confidence in the company, as insiders typically possess insights into their firm's operations that are not available to the public. Gilead Sciences, a biopharmaceutical company based in Foster City, California, focuses on developing medicines for unmet medical needs, particularly in virology, oncology, and other therapeutic areas. The firm has a robust portfolio, including products like Biktarvy and Veklury, and employs approximately 17,600 people worldwide.
As of November 13, 2025, Gilead's market capitalization stands at $156.7 billion, with a price-to-earnings ratio of 19.32 and an earnings per share of 6.43. The company is set to announce its upcoming earnings on April 21, 2026, with an estimated EPS of $2.07 and revenue of $7.2 billion.
While insider buying can be a positive signal, it is essential for investors to consider these transactions in the broader context of multiple insiders and overall market conditions. Such decisions reflect individual perspectives and should be evaluated alongside other fundamental and technical indicators.